Prenetics Global (PRE, Financial) experienced a sharp stock decline, falling by 5.47%. The share price is now $4.67 with a trading volume of 427 shares. Recent financial reports show Prenetics has earned a revenue of $5.94 million, with a net loss of $10.80 million, resulting in a loss per share of $0.88 and a gross profit of $2.03 million. The price-to-earnings ratio stands at -1.18. Despite these figures, the sole institution covering the stock recommends buying, without any hold or sell advice.
In the broader life sciences sector, there was a general decline of 1.73%. However, related stocks like Endra Life Sciences Inc. and Bioaffinity Technologies Inc. showed significant gains. Some stocks recorded considerable trading activity, such as Endra Life Sciences Inc. with a turnover rate of 1,887.67% and Ispecimen Inc. at 71.50%. Notably, Endra Life Sciences Inc. had the highest price volatility.
Prenetics Global focuses on diagnostics and genetic testing, aiming to improve global health through accessible preventive and personalized care services. Operating in regions like the UK, Hong Kong, India, South Africa, and Southeast Asia, its services include consumer genetic testing, early colorectal cancer screening, COVID-19 testing, and medical diagnostics.
